RedHill Biopharma Ltd. provided earnings guidance for fourth quarter of 2021. For the quarter, the company record Q4/2021 total net revenues estimated to be in the range of $22-24 million vs. $21.6 million in Q3/2021 and $21.5 in Q4/2020.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.4254 USD | -1.50% | -4.94% | -70.86% |
06-06 | RedHill Biopharma Ltd. Announces Resignation of Alla Felders as Member of the Board | CI |
05-06 | Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib | MT |
1st Jan change | Capi. | |
---|---|---|
-70.86% | 13.76M | |
+0.82% | 91.94B | |
-3.16% | 38.74B | |
+64.83% | 26.66B | |
-12.43% | 15.32B | |
-5.81% | 13.3B | |
-11.38% | 11.65B | |
+156.85% | 10.37B | |
-49.84% | 10.12B | |
+2.32% | 9.06B |
- Stock Market
- Equities
- RDHL Stock
- News RedHill Biopharma Ltd.
- Redhill Biopharma Ltd. Provides Earnings Guidance for Fourth Quarter of 2021